Keyphrases
Therapeutic Strategies
100%
DNA Nanoparticles
100%
Immunomodulation
100%
Oral Insulin
100%
Diabetes
100%
Faculty Development
62%
Grant Program
62%
Insulin
37%
Stomach
37%
Insulin Peptides
37%
Non-obese Diabetic Mice
37%
Oral Delivery
25%
Nanoparticles
25%
Plasmid DNA (pDNA)
25%
Immune Tolerance
25%
Insulin Secretion
25%
Hyperglycemia
25%
Chitosan Nanoparticles
25%
Vascular Complications
25%
Type 1 Diabetes Mellitus (T1DM)
25%
Viral Vectors
12%
Management Challenges
12%
Large Components
12%
Weight Loss
12%
Spleen
12%
American Diabetes Association
12%
Newly Diagnosed Patients
12%
Foodstuffs
12%
Serum IgE
12%
Human Leukocyte Antigen
12%
Peripheral Resistance
12%
Patient Education
12%
Newly Diagnosed
12%
Nocturia
12%
Diabetic Ketoacidosis
12%
B Cells
12%
Pancreatic β-cells
12%
Oral Formulation
12%
Glycemic Control
12%
Reduced Immunogenicity
12%
Pain Management
12%
Lymphocytes
12%
New Therapeutics
12%
Therapeutic Potential
12%
Polydipsia
12%
Equivalent Target
12%
Clinical Management
12%
Insulin Dose
12%
Undiagnosed Diabetes
12%
Nonspecific Immune Response
12%
Intradermal Injection
12%
Doctor's Office
12%
Blurred Vision
12%
Proinsulin
12%
Polyuria
12%
Diabetes Costs
12%
Cell Resistance
12%
Office Visits
12%
Hospital Inpatient Care
12%
Paid Care
12%
Gene Therapy
12%
Antigenicity
12%
Immune Response
12%
Natural Polysaccharides
12%
Immunodominant
12%
Diabetes Diagnosis
12%
Intestine
12%
Diabetes Patients
12%
Autoimmune
12%
Adoptive Transfer
12%
Therapeutic Levels
12%
Chitosan
12%
Human Factor VIII
12%
Type I Diabetes
12%
Immunomodulatory
12%
DNA Delivery
12%
Oral Tolerance
12%
Haemophilia A Mice
12%
Re-administration
12%
Small Intestine
12%
Coagulation
12%
Autoimmune Disease
12%
Diabetes Type 1
12%
Carbohydrate Metabolism
12%
DRB1
12%
Immune Regulation
12%
Clinical Trials
12%
Patient Management
12%
Antigen-specific
12%
Prescription Drugs
12%
T Cells
12%
Transplantation
12%
Healthcare Professionals
12%
Proposed Strategy
12%
Health Systems
12%
Treatment Adherence
12%
Encoded Protein
12%
Health Care Delivery
12%
DNA Encoding
12%
Type 1 Diabetes Patients
12%
INIS
insulin
100%
nanoparticles
100%
dna
100%
patients
27%
mice
27%
peptides
22%
delivery
18%
stomach
13%
cost
13%
antigens
9%
immune tolerance
9%
proposals
9%
management
9%
hyperglycemia
9%
secretion
9%
boron 9
9%
plasmids
9%
tolerance
9%
hypothesis
9%
losses
9%
Medicine and Dentistry
Nanoparticle
50%
Diabetes
50%
Immunomodulation
50%
Blood Clotting Factor 8
16%
Health Care Cost
16%
Ob/Ob Mouse
16%
Immunological Tolerance
11%
Chitosan Nanoparticle
11%
Plasmid DNA
11%
Insulin Release
11%
Beta Cell
11%
Insulin Dependent Diabetes Mellitus
11%
Hyperglycemia
11%
Intradermal Drug Administration
5%
Polysaccharide
5%
Human Leukocyte Antigen
5%
Oral Tolerance
5%
Proinsulin
5%
Polydipsia
5%
Microvascular Complication
5%
Prescription Medication
5%
Polyuria
5%
Nocturia
5%
Delivery of Health Care
5%
Blurred Vision
5%
Diabetic Ketoacidosis
5%
Virus Vector
5%
Clinical Study
5%
Small Intestine
5%
T Cell
5%
Antigen Specificity
5%
Adoptive Transfer
5%
Vascular Resistance
5%
Haemophilia A
5%
Physician
5%
Gene Therapy
5%
Clinical Management
5%
Glycemic Control
5%
Clinical Trial
5%
Hospital Inpatient
5%
Chitosan
5%
Patient Care
5%
Lymphocyte
5%
Gene Targeting
5%
Diabetes Mellitus
5%
Autoimmune Disease
5%
Intestine
5%
Health Care
5%
Immune Response
5%
Symptom
5%
Carbohydrate Metabolism
5%
Antigenicity
5%
Immunogenicity
5%